<?xml version="1.0" encoding="ISO-8859-1"?>
<!DOCTYPE ichicsr SYSTEM "http://www.accessdata.fda.gov/xml/icsr-xml-v2.1.dtd">
<ichicsr lang="en">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4053171_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20121211134151</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>2</safetyreportversion>
		<safetyreportid>PHHY2012CA003830</safetyreportid>
		<primarysourcecountry>CA</primarysourcecountry>
		<occurcountry>CA</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>20121210</transmissiondate>
		<reporttype>1</reporttype>
		<serious>1</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>20120110</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>20121206</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHHY2012CA003830</companynumb>
		<medicallyconfirm>2</medicallyconfirm>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>CA</reportercountry>
			<qualification>5</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<qualification>5</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<qualification>1</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>CA</reportercountry>
			<qualification>5</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>KB</patientinitial>
			<patientbirthdateformat>102</patientbirthdateformat>
			<patientbirthdate>19930826</patientbirthdate>
			<patientweight>61.224</patientweight>
			<patientheight>140</patientheight>
			<patientsex>2</patientsex>
			<reaction>
				<primarysourcereaction>Experienced 1 menstruation period within the last year</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Oligomenorrhoea</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Oligomenorrhoea</reactionmeddrapt>
				<reactionoutcome>6</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Increased number of lesions</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Brain lesion</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Central nervous system lesion</reactionmeddrapt>
				<reactionoutcome>6</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Pain upon injection thighs and buttocks / Painful burning injection/ Intense pain</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Injection site pain</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Injection site pain</reactionmeddrapt>
				<reactionoutcome>6</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Pinpoint bruises at injection sites</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Injection site bruising</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Injection site haematoma</reactionmeddrapt>
				<reactionoutcome>2</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Nausea</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Nausea</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Nausea</reactionmeddrapt>
				<reactionfirsttime>134</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionoutcome>6</reactionoutcome>
			</reaction>
			<test>
				<testname>Nuclear magnetic resonance imaging</testname>
				<moreinformation>1</moreinformation>
			</test>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>EXTAVIA</medicinalproduct>
				<obtaindrugcountry>CA</obtaindrugcountry>
				<drugauthorizationnumb>BLA 125290</drugauthorizationnumb>
				<drugauthorizationcountry>CA</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>8</drugstructuredosagenumb>
				<drugstructuredosageunit>027</drugstructuredosageunit>
				<drugdosagetext>8 MIU, QOD</drugdosagetext>
				<drugdosageform>Solution For Injection</drugdosageform>
				<drugadministrationroute>058</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Relapsing-remitting multiple sclerosis</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20111129</drugstartdate>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>INTERFERON BETA-1B</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Central nervous system lesion</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Central nervous system lesion</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Injection site haematoma</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Injection site haematoma</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Injection site pain</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Injection site pain</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Nausea</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Nausea</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Oligomenorrhoea</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Oligomenorrhoea</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHHY2012CA003830, is an initial spontaneous report from a consumer received on 10 Jan 2012 via Extavia Extracare Marketing Program and follow up report received from a consumer on 20 Jan 2012. Follow-up report from a consumer (patient) received on 10 Apr 2012 via Extavia Extracare marketing program. Follow up report received from a consumer (patient's father) on 14 Oct 2012 and follow up report from quality complaint department (QA) received on 06 Dec 2012. This is also a quality complaint report (#CAPC12-00704 / 568686). This report refers to an 18-year-old female patient (ID EA000170). The patient's medical history and concomitant medications were not reported. The patient received Extavia (interferon beta-1b) for the treatment of relapsing-remitting multiple sclerosis from 29 Nov 2011 at a dose of 8 MIU, every other day, subcutaneous. On an unknown date, after starting the suspect drug the patient experienced (during the last two or three injections of the drug) pain upon injection on thighs and buttocks that lasted about 1 hour. The patient also reported pinpoint bruises at injection sites and painful burning injection that used to be pain free. During the follow-up call, the patient reported that when she injected in her thighs, she had an intense pain in the thigh that lasted about one minute and was strong enough to cause her nausea. The patient experienced 1 menstruation period within the last year and wonder if the medication can influence. The reporter also wondered how long it may take before that he could see that the medication was working, since her daughter's last MRI showed increased number of lesions. From the QA department it was reported that a root cause could not be determined, as no batch number was provided in the complaint to allow a root cause investigation. Based on the absence of potency&#8208;related deviations, and stability data confirming no changes or trend in potency, it was unlikely that there was a technical basis for the complaint. Without a known lot number or receipt of sample, a more complete assessment could not be completed. As no lot number or sample has been provided, a comprehensive assessment of recurrence could not be determined. Furthermore, a query of AQWA indicated there had been no potency related out of specification results/deviations in the past two years, and a Sep 2012 review of stability data indicated no trends or changes in potency. No corrective or preventive action was indicated. Based on the results of the investigation, QA department considered the complaint to be not justified. Outcome for the event pinpoint bruises at injection sites was condition improving. Outcome for remaining events was not reported. Seriousness and causality were not reported. 

Follow up report received from a consumer on 20 Jan 2012: Updated event information.

Follow-up report from a consumer (patient) received on 10 Apr 2012 via Extavia Extracare marketing program. Updated new event (nausea).

Follow up report received from a consumer (patient's father) on 14 Oct 2012. New events (Increased number of lesions - One menstruation period within the last year) were added.

Follow up report from quality complaint department received on 06 Dec 2012: Updated investigation summary.</narrativeincludeclinical>
				<sendercomment>MAC: Review of available reported data does not allow for a proper causality assessment. </sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr>
